SOPHiA GENETICS Reports Fourth Quarter and Full Year 2023 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
SOPHiA GENETICS SA (SOPH) Misses Q4 EPS by 15c, Misses on Revenue; Offers FY24 Revenue Guidance
March 5, 2024 6:48 AM ESTSOPHiA GENETICS SA (NASDAQ: SOPH) reported Q4 EPS of ($0.37), $0.15 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $17 million versus the consensus estimate of $17.33 million.
GUIDANCE:
SOPHiA GENETICS SA sees FY2024 revenue of $78-81 million, versus the... More
